vs

Side-by-side financial comparison of FRANKLIN COVEY CO (FC) and GYRE THERAPEUTICS, INC. (GYRE). Click either name above to swap in a different company.

FRANKLIN COVEY CO is the larger business by last-quarter revenue ($64.0M vs $37.2M, roughly 1.7× GYRE THERAPEUTICS, INC.). GYRE THERAPEUTICS, INC. runs the higher net margin — -3.7% vs -5.1%, a 1.5% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs -7.3%). FRANKLIN COVEY CO produced more free cash flow last quarter ($-1.6M vs $-5.8M). Over the past eight quarters, GYRE THERAPEUTICS, INC.'s revenue compounded faster (17.0% CAGR vs 2.2%).

Franklin Covey Co., trading as FranklinCovey and based in Salt Lake City, Utah, is a coaching company which provides training and assessment services in the areas of leadership, individual effectiveness, and business execution for organizations and individuals. The company was formed on May 30, 1997, as a result of merger between Hyrum W. Smith's Franklin Quest and Stephen R. Covey's Covey Leadership Center. Among other products, the company has marketed the FranklinCovey planning system, mod...

GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.

FC vs GYRE — Head-to-Head

Bigger by revenue
FC
FC
1.7× larger
FC
$64.0M
$37.2M
GYRE
Growing faster (revenue YoY)
GYRE
GYRE
+40.7% gap
GYRE
33.4%
-7.3%
FC
Higher net margin
GYRE
GYRE
1.5% more per $
GYRE
-3.7%
-5.1%
FC
More free cash flow
FC
FC
$4.1M more FCF
FC
$-1.6M
$-5.8M
GYRE
Faster 2-yr revenue CAGR
GYRE
GYRE
Annualised
GYRE
17.0%
2.2%
FC

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
FC
FC
GYRE
GYRE
Revenue
$64.0M
$37.2M
Net Profit
$-3.3M
$-1.4M
Gross Margin
75.5%
95.3%
Operating Margin
-5.7%
0.3%
Net Margin
-5.1%
-3.7%
Revenue YoY
-7.3%
33.4%
Net Profit YoY
-378.5%
-340.1%
EPS (diluted)
$-0.27
$-0.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FC
FC
GYRE
GYRE
Q4 25
$64.0M
$37.2M
Q3 25
$71.2M
$30.6M
Q2 25
$67.1M
$26.8M
Q1 25
$59.6M
$22.1M
Q4 24
$69.1M
$27.9M
Q3 24
$84.1M
$25.5M
Q2 24
$73.4M
$25.2M
Q1 24
$61.3M
$27.2M
Net Profit
FC
FC
GYRE
GYRE
Q4 25
$-3.3M
$-1.4M
Q3 25
$4.4M
$5.9M
Q2 25
$-1.4M
$1.6M
Q1 25
$-1.1M
$3.7M
Q4 24
$1.2M
$569.0K
Q3 24
$12.0M
$2.9M
Q2 24
$5.7M
$4.5M
Q1 24
$874.0K
$9.9M
Gross Margin
FC
FC
GYRE
GYRE
Q4 25
75.5%
95.3%
Q3 25
75.5%
94.7%
Q2 25
76.5%
95.7%
Q1 25
76.7%
95.9%
Q4 24
76.3%
95.8%
Q3 24
78.1%
96.2%
Q2 24
76.6%
96.9%
Q1 24
76.4%
96.4%
Operating Margin
FC
FC
GYRE
GYRE
Q4 25
-5.7%
0.3%
Q3 25
11.1%
22.7%
Q2 25
-3.3%
8.1%
Q1 25
-2.4%
10.3%
Q4 24
2.1%
2.4%
Q3 24
21.3%
16.6%
Q2 24
11.4%
12.7%
Q1 24
2.4%
29.7%
Net Margin
FC
FC
GYRE
GYRE
Q4 25
-5.1%
-3.7%
Q3 25
6.1%
19.4%
Q2 25
-2.1%
5.9%
Q1 25
-1.8%
16.9%
Q4 24
1.7%
2.0%
Q3 24
14.2%
11.2%
Q2 24
7.8%
18.0%
Q1 24
1.4%
36.6%
EPS (diluted)
FC
FC
GYRE
GYRE
Q4 25
$-0.27
$-0.01
Q3 25
$0.34
$0.03
Q2 25
$-0.11
$0.00
Q1 25
$-0.08
$0.00
Q4 24
$0.09
$0.00
Q3 24
$0.89
$0.01
Q2 24
$0.43
$0.01
Q1 24
$0.06
$0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FC
FC
GYRE
GYRE
Cash + ST InvestmentsLiquidity on hand
$17.5M
$52.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$54.0M
$106.0M
Total Assets
$221.3M
$166.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FC
FC
GYRE
GYRE
Q4 25
$17.5M
$52.4M
Q3 25
$31.7M
$60.0M
Q2 25
$33.7M
$54.4M
Q1 25
$40.4M
$29.9M
Q4 24
$53.3M
$26.7M
Q3 24
$48.7M
$25.1M
Q2 24
$36.6M
$25.1M
Q1 24
$40.9M
$37.4M
Stockholders' Equity
FC
FC
GYRE
GYRE
Q4 25
$54.0M
$106.0M
Q3 25
$66.9M
$101.9M
Q2 25
$65.6M
$92.0M
Q1 25
$72.5M
$68.1M
Q4 24
$80.6M
$63.3M
Q3 24
$83.1M
$63.2M
Q2 24
$72.2M
$60.4M
Q1 24
$70.8M
$56.6M
Total Assets
FC
FC
GYRE
GYRE
Q4 25
$221.3M
$166.1M
Q3 25
$242.9M
$159.4M
Q2 25
$218.3M
$152.6M
Q1 25
$221.3M
$129.8M
Q4 24
$239.9M
$125.4M
Q3 24
$261.5M
$125.2M
Q2 24
$221.0M
$120.9M
Q1 24
$221.9M
$122.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FC
FC
GYRE
GYRE
Operating Cash FlowLast quarter
$98.0K
$-5.6M
Free Cash FlowOCF − Capex
$-1.6M
$-5.8M
FCF MarginFCF / Revenue
-2.5%
-15.5%
Capex IntensityCapex / Revenue
2.7%
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$5.9M
$-180.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FC
FC
GYRE
GYRE
Q4 25
$98.0K
$-5.6M
Q3 25
$9.9M
$4.7M
Q2 25
$6.3M
$2.1M
Q1 25
$-1.4M
$-129.0K
Q4 24
$14.1M
$-2.8M
Q3 24
$21.9M
$1.7M
Q2 24
$8.2M
$-5.5M
Q1 24
$12.8M
$2.9M
Free Cash Flow
FC
FC
GYRE
GYRE
Q4 25
$-1.6M
$-5.8M
Q3 25
$5.7M
$4.0M
Q2 25
$4.5M
$1.8M
Q1 25
$-2.6M
$-251.0K
Q4 24
$13.1M
$-2.8M
Q3 24
$20.8M
$1.0M
Q2 24
$7.3M
$-6.9M
Q1 24
$12.1M
$2.7M
FCF Margin
FC
FC
GYRE
GYRE
Q4 25
-2.5%
-15.5%
Q3 25
8.0%
13.1%
Q2 25
6.7%
6.8%
Q1 25
-4.4%
-1.1%
Q4 24
19.0%
-10.1%
Q3 24
24.7%
4.1%
Q2 24
9.9%
-27.5%
Q1 24
19.8%
9.8%
Capex Intensity
FC
FC
GYRE
GYRE
Q4 25
2.7%
0.4%
Q3 25
5.9%
2.2%
Q2 25
2.7%
1.0%
Q1 25
2.1%
0.6%
Q4 24
1.4%
0.2%
Q3 24
1.3%
2.7%
Q2 24
1.2%
5.8%
Q1 24
1.0%
0.9%
Cash Conversion
FC
FC
GYRE
GYRE
Q4 25
Q3 25
2.27×
0.79×
Q2 25
1.32×
Q1 25
-0.03×
Q4 24
11.98×
-4.85×
Q3 24
1.83×
0.60×
Q2 24
1.43×
-1.21×
Q1 24
14.62×
0.29×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons